echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > CCSC: Kylin Club International Connection—Stars are dazzling, big names gather to explore the international clinical application of CAR-T—Special session of Jiangsu Provincial People's Hospital

    CCSC: Kylin Club International Connection—Stars are dazzling, big names gather to explore the international clinical application of CAR-T—Special session of Jiangsu Provincial People's Hospital

    • Last Update: 2021-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, chimeric antigen receptor T cells (CAR-T) have been effective in treating lymphoma and leukemia.
    A large number of clinical trials and studies have promoted the rapid development of CAR-T cell therapy.
    However, the approved CAR-T cell drugs in China are still In the blank period
    .

    On June 22, 2021, the National Medical Products Administration (NMPA) officially approved Fosun Kate’s CD19 autologous CAR-T cell therapy drug Yikaida® (Akilunza injection) to fill the domestic long-term CAR-T drug Blank, as the first CAR-T cell therapy approved for marketing in China, it is used to treat adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after receiving second-line or above systemic treatment.
    /R LBCL patients bring new hope for long-term survival
    .

    Domestic and foreign research data show that the best overall response rate of Yikaida® is 79.
    2%, the objective response rate is 83%, the complete response rate is 58%, and the 4-year overall survival rate is 44%, which significantly improves the overall survival of patients.
    Quality of life
    .

    From 20:00-21:50 on September 18th, we will invite experts and scholars in the field of hematology: Professor Li Jianyong from Jiangsu Provincial People's Hospital to serve as the chairperson; invite Prof.
    Lin Yi from Mayo Clinic Rochester District to share foreign practical experience, Jiangsu Province Professor Xu Wei from the People’s Hospital conducted an interpretation of the real-world evidence for CAR-T treatment of lymphoma; at the same time, Professor Wang Li, Professor Cao Lei, Professor Liang Jinhua, Professor Miao Yi, Professor Peng Chen, Professor Shen Haorui, and Wang Sanmei were specially invited Professors, Professor Wu Jiazhu, Professor Wu Wei, Professor Xia Yi, Professor Yin Hua, and Professor Zhao Xiaoli served as panellists, bringing us an academic feast together
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.